References
- Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239
- DeBacker G, Ambosioni E, Borch-Johnson K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-1610
- Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565
- Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207
- Gold MR, Siegel JE, Russell LB, et al., eds. Cost-effectiveness in Health and Medicine. Oxford: Oxford University Press, 2006
- Ford I, Murray H, Packard CJ, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007;357:1477-1486
- Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007;11:1-160, iii-iv
- Glynn RJ, Danielson E, Fonseca FAH, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009;360:1-11
- Aries E. United States life tables, 2004. Natl Vital Stat Rep 2007;56(9)9:1–39. (http://www.cdc.gov/nchs/data/nvsr/nvsr56/nvsr56_09.pdf, accessed 12/12/2008)
- Heron M. Deaths: leading causes for 2004. Natl Vital Stat Rep 2007;56(5)9:1–95. (http://www.cdc.gov/nchs/data/nvsr/nvsr56/nvsr56_05.pdf, accessed 12/12/2008)
- Framingham Heart Study 2008. Coronary Heart Disease (10-year risk). (http://www.framinghamheartstudy.org/risk/coronary.html, accessed 4/23/09)
- Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998;279:1458-1462
- Food and Drug Administration, Center for Drug Evaluation and Research. Generic Competition and Drug Prices http://www.fda.gov/CDER/ogd/generic_competition.htm, accessed 5/3/2007
- U.S. Department of Labor, Bureau of Labor Statistics 2009. Consumer Price Index Databases – Urban Consumers (All Items) (http://www.bls.gov/cpi/data.htm, accessed 4/1/09)
- Sullivan P, Arant T, Ellis S, et al. The cost-effectiveness analysis of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics 2006;10:1021-1033
- Shih YT, Han S, Cantor SB. Impact of generic drug entry on cost-effectiveness analysis. Med Decis Making 2005;25:71-80
- Hoyle M. Future drug prices and cost-effectiveness analyses. Pharmacoeconomics 2008;26:589-602
- Pharmaceutical Management Agency. Prescription for pharmacoeconomic analysis. Methods for cost-utility analysis. (http://www.pharmac.govt.nz/schedule.asp. accessed 12/4/2009)
- Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn’t it increase at the rate of inflation? Arch Intern Med 2003;163:1637-1641
- Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000;20:332-342
- Cutler DM, Rosen AB, Vijan S. The value of medical spending in the United States, 1960–2000. N Engl J Med 2006;355:920-927
- Heart Protection Study Collaborative Group. Statin cost-effectiveness in the United States for people at different vascular risk levels. Circ Cardiovasc Qual Outcomes 2009;2:65-72
- Pignone M, Earnshaw S, Tice J, et al. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med 2006;144:326-336
- US National Hospital Discharge Survey. 2006. Available at http://www.cdc.gov/nchs/about/major/hdasd/nhds.htm
- Society of Cardiothoracic Surgeons of Great Britain and Ireland. UK Cardiac Surgical register. 2006. Available at http://www.scts.org
- British Cardiovascular Intervention Society. PCI Database. 2005. Available at http://www.bcis.org.uk
- Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med 2005;142:251-259
- Beinart SC, Kolm P, Veledar E, et al. Long-term cost-effectiveness analysis of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention. J Am Coll Cardiol 2005;46:761-769
- Chan PS, Nallamothu BK, Gurm HS, et al. Incremental benefit and cost-effectiveness of high dose statin therapy in high risk patients with coronary heart disease. Circulation 2007;115:2398-2409
- Kauf TL, Velazquez EJ, Crosslin DR, et al. The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry. Am Heart J 2006;151:206-212
- Puskas JD, Williams WH, Mahoney EM, et al. Off-pump vs. conventional coronary artery bypass grafting: early and 1-year graft patency, cost, and quality-of-life outcomes. JAMA 2004;291:1841-1849
- O'Brien C, Gage B. Cost and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 2005;293:699-706
- Lee WC, Christensen MC, Josh, AV, et al. Long-term cost of stroke subtypes among Medicare beneficiaries. Cerebrovasc Dis 2007;23:57-65
- Scuffham PA, Kosa J. The cost-effectiveness of fluvastatin in Hungary following successful percutaneous coronary intervention. Cardiovasc Drugs Ther 2006;20:309-317